Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Unknown 3

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 32Gastrointestinal 16Head & Neck 11Sarcoma 4Lymphoid 3Dermatologic 3Breast 3Gynecologic 2CNS 2

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × endostar protein × Breast × Clear all
NCT01907529 2019-08-09

TENDENCY

Hebei Medical University Fourth Hospital

Phase 2/3 Unknown
300 enrolled
Breast

Breast Neoplasms

NCT03907098 2019-04-08

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Zhejiang Cancer Hospital

Phase 2 Unknown
50 enrolled
Breast

Breast Neoplasms

NCT02865304 2016-08-12

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Fujian Cancer Hospital

Phase 3 Unknown
80 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡